J Schneider

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
    J Schneider
    Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, UK
    Nat Med 4:397-402. 1998
  2. ncbi Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice
    T Hanke
    Molecular Immunology Group, Institute of Molecular Medicine, University of Oxford, The John Radcliffe, UK
    J Gen Virol 79:83-90. 1998
  3. ncbi Induction of CD8+ T cells using heterologous prime-boost immunisation strategies
    J Schneider
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, UK
    Immunol Rev 170:29-38. 1999
  4. ncbi A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees
    J Schneider
    Molecular Immunology Group, Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, OX3 9DU, Oxford, UK
    Vaccine 19:4595-602. 2001
  5. ncbi Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use
    M Plebanski
    Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, GB
    Eur J Immunol 28:4345-55. 1998
  6. ncbi Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
    V S Moorthy
    Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK
    Vaccine 21:1995-2002. 2003
  7. ncbi Strong HLA class I--restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?
    H Loke
    Nuffield Department of Medicine, John Radcliffe Hospital and Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    J Infect Dis 184:1369-73. 2001
  8. ncbi A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge
    S J Dunachie
    University of Oxford, Nuffield Department of Clinical Medicine, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Rd, Headington, Oxford OX3 7LJ, United Kingdom
    Infect Immun 74:5933-42. 2006
  9. ncbi Isolation, cloning, and sequencing of simian foamy viruses from chimpanzees (SFVcpz): high homology to human foamy virus (HFV)
    O Herchenröder
    Department of Medical Pathology, University of California, Davis 95616
    Virology 201:187-99. 1994
  10. ncbi Antifungal and antitumor activities of a monoclonal antibody directed against a stress mannoprotein of Candida albicans
    M J Omaetxebarria
    Departamento de Inmunologia, Microbiologia y Parasitologia, Facultad de Medicina y Odontologia, Universidad del Pais Vasco, Bilbao, Vizcaya, Spain
    Curr Mol Med 5:393-401. 2005

Collaborators

Detail Information

Publications11

  1. ncbi Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
    J Schneider
    Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, UK
    Nat Med 4:397-402. 1998
    ..DNA priming followed by MVA boosting may provide a general immunization regime for induction of high levels of CD8+ T cells...
  2. ncbi Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice
    T Hanke
    Molecular Immunology Group, Institute of Molecular Medicine, University of Oxford, The John Radcliffe, UK
    J Gen Virol 79:83-90. 1998
    ..Also, the correct processing and presentation of some HLA-restricted epitopes in human cells was confirmed...
  3. ncbi Induction of CD8+ T cells using heterologous prime-boost immunisation strategies
    J Schneider
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, UK
    Immunol Rev 170:29-38. 1999
    ..Possible mechanisms explaining why heterologous prime-boost strategies, in particular boosting with replication-impaired recombinant poxviruses, are so effective are discussed...
  4. ncbi A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees
    J Schneider
    Molecular Immunology Group, Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, OX3 9DU, Oxford, UK
    Vaccine 19:4595-602. 2001
    ..The high immunogenicity of this prime-boost regimen in chimpanzees supports further assessment of this delivery strategy for the induction of protection against P. falciparum malaria in humans...
  5. ncbi Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use
    M Plebanski
    Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, GB
    Eur J Immunol 28:4345-55. 1998
    ..Thus, the novel recombinant Ty/MVA prime/boost combination with these constructs provides a safe alternative for evaluation for human vaccination against P. falciparum malaria...
  6. ncbi Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
    V S Moorthy
    Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK
    Vaccine 21:1995-2002. 2003
    ..The MVA vaccine was administered intradermally by needle. The vaccines were well-tolerated by all three routes and in various DNA/MVA immunisation regimes. There were no severe or serious adverse events...
  7. ncbi Strong HLA class I--restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?
    H Loke
    Nuffield Department of Medicine, John Radcliffe Hospital and Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    J Infect Dis 184:1369-73. 2001
    ..The potentially pathogenic role of serotype-cross-reactive CD8 T cells poses yet another obstacle to successful dengue vaccine development...
  8. ncbi A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge
    S J Dunachie
    University of Oxford, Nuffield Department of Clinical Medicine, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Rd, Headington, Oxford OX3 7LJ, United Kingdom
    Infect Immun 74:5933-42. 2006
    ..033). No protection was observed in the DDM-CS group. Prime-boost vaccination with DNA and MVA encoding ME-TRAP but not CS resulted in partial protection against P. falciparum sporozoite challenge in the present study...
  9. ncbi Isolation, cloning, and sequencing of simian foamy viruses from chimpanzees (SFVcpz): high homology to human foamy virus (HFV)
    O Herchenröder
    Department of Medical Pathology, University of California, Davis 95616
    Virology 201:187-99. 1994
    ..Based on sequence comparisons in this report, primate foamy viruses may be arranged into different clusters with SFVcpz and HFV forming one cluster and SFV-1 and SFV-3 as prototypes for two unique clusters...
  10. ncbi Antifungal and antitumor activities of a monoclonal antibody directed against a stress mannoprotein of Candida albicans
    M J Omaetxebarria
    Departamento de Inmunologia, Microbiologia y Parasitologia, Facultad de Medicina y Odontologia, Universidad del Pais Vasco, Bilbao, Vizcaya, Spain
    Curr Mol Med 5:393-401. 2005
    ..albicans, direct candidacidal activity and direct tumoricidal activity. In tumor cells, Mab C7 reacted with nucleoporin Nup88, a reactivity that can be utilized for diagnostic and prognostic purposes...
  11. ncbi Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus
    J Schneider
    J Gen Virol 67:2533-8. 1986
    ..Furthermore gp120 was precipitated by sera from horses infected with equine infectious anaemia virus (EIAV), but not by sera from uninfected animals. This may indicate conserved epitopes common to the envelopes of HIV and EIAV...